Phoenix Financial Ltd. Has $632.88 Million Stock Position in Teva Pharmaceutical Industries Ltd. $TEVA

Key Points

• Phoenix Financial Ltd. has increased its stake in Teva Pharmaceutical Industries by 31.7%, owning 37,761,444 shares valued at approximately $632.88 million.
• Recent analyst upgrades include a shift from a "buy" to a "strong buy" rating for Teva by Wall Street Zen, with target prices set between $23.00 and $26.00 by several firms.
• Teva's shares opened at $19.43 with a market cap of $22.28 billion, after recently reporting earnings exceeding analyst expectations.

Phoenix Financial Ltd. boosted its holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 31.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,761,444 shares of the company's stock after purchasing an additional 9,094,372 shares during the quarter. Teva Pharmaceutical Industries makes up approximately 8.4% of Phoenix Financial Ltd.'s holdings, making the stock its biggest position. Phoenix Financial Ltd. owned 3.29% of Teva Pharmaceutical Industries worth $632,882,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. US Bancorp DE boosted its position in shares of Teva Pharmaceutical Industries by 6.5% during the 1st quarter. US Bancorp DE now owns 10,812 shares of the company's stock valued at $166,000 after acquiring an additional 656 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 15.0% during the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,474 shares of the company's stock valued at $92,000 after acquiring an additional 715 shares during the last quarter. CWM LLC boosted its position in shares of Teva Pharmaceutical Industries by 18.1% during the 2nd quarter. CWM LLC now owns 4,995 shares of the company's stock valued at $84,000 after acquiring an additional 767 shares during the last quarter. Factorial Partners LLC boosted its position in shares of Teva Pharmaceutical Industries by 0.3% during the 1st quarter. Factorial Partners LLC now owns 333,000 shares of the company's stock valued at $5,118,000 after acquiring an additional 1,000 shares during the last quarter. Finally, Swedbank AB boosted its position in shares of Teva Pharmaceutical Industries by 1.1% during the 2nd quarter. Swedbank AB now owns 110,653 shares of the company's stock valued at $1,855,000 after acquiring an additional 1,244 shares during the last quarter. 54.05% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, insider Eric A. Hughes sold 52,742 shares of the firm's stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $799,568.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Placid Jover sold 6,053 shares of the stock in a transaction on Friday, August 1st. The stock was sold at an average price of $15.16, for a total value of $91,763.48. Following the completion of the sale, the insider owned 6,774 shares in the company, valued at approximately $102,693.84. The trade was a 47.19% decrease in their position. The disclosure for this sale can be found here. 0.55% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Wall Street Zen upgraded Teva Pharmaceutical Industries from a "buy" rating to a "strong-buy" rating in a research report on Saturday, October 11th. JPMorgan Chase & Co. increased their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company an "overweight" rating in a research report on Friday, October 3rd. Weiss Ratings reiterated a "sell (d-)" rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, October 8th. Finally, UBS Group increased their target price on Teva Pharmaceutical Industries from $23.00 to $26.00 and gave the company a "buy" rating in a research report on Wednesday, September 24th. Two research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and an average price target of $25.57.

Teva Pharmaceutical Industries Stock Up 0.6%

Shares of TEVA opened at $19.43 on Tuesday. The company has a market cap of $22.28 billion, a PE ratio of -121.41, a P/E/G ratio of 1.06 and a beta of 0.71. The business has a fifty day moving average of $18.95 and a 200 day moving average of $17.17. Teva Pharmaceutical Industries Ltd. has a 52-week low of $12.47 and a 52-week high of $22.80. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last issued its quarterly earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.64 by $0.02. The company had revenue of $4.18 billion during the quarter, compared to the consensus estimate of $4.34 billion. Teva Pharmaceutical Industries had a positive return on equity of 46.10% and a negative net margin of 0.95%.Teva Pharmaceutical Industries's revenue was up .3% on a year-over-year basis. During the same period last year, the company earned $0.61 earnings per share. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. On average, sell-side analysts expect that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current year.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.